论文部分内容阅读
单克隆抗体治疗卵巢癌的实验与临床研究均已取得较大进展。贝伐单抗(nevacizumab,BEV)通过抑制新生血管形成,达到抑制肿瘤的目的;曲妥珠单抗(trastuzumab)、帕妥珠单抗(pertuzumab)选择性作用于人类表皮生长因子受体2,抑制肿瘤细胞的生长;西妥昔单抗(cetuximab)通过结合细胞表皮生长因子受体1,抑制细胞增殖、诱导凋亡;oregovomab通过与CA125形成免疫复合物,引起针对CA125的独特型免疫应答。单克隆抗体治疗卵巢癌可弥补传统治疗的不足。综述单克隆抗体治疗卵巢癌的研究进展。
Much progress has been made in the experimental and clinical studies of monoclonal antibody in the treatment of ovarian cancer. Bevacizumab (BEV) can inhibit tumor by inhibiting neovascularization. Trastuzumab and pertuzumab selectively act on human epidermal growth factor receptor 2, Inhibits tumor cell growth; cetuximab inhibits cell proliferation and induces apoptosis by binding to cell epidermal growth factor receptor 1; oregovomab causes an idiotypic immune response against CA125 by forming an immune complex with CA125. Monoclonal antibody treatment of ovarian cancer can make up for the lack of traditional treatment. Review of Monoclonal Antibodies in the Treatment of Ovarian Cancer.